UnitedHealth Group Valuation
Is UNH * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of UNH * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: UNH * (MX$8310) is trading below our estimate of fair value (MX$14784.68)
Significantly Below Fair Value: UNH * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UNH *?
Other financial metrics that can be useful for relative valuation.
What is UNH *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$445.42b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.3x |
Enterprise Value/EBITDA | 14.1x |
PEG Ratio | 1.5x |
Price to Earnings Ratio vs Peers
How does UNH *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 18x | ||
ELV Elevance Health | 19.6x | 12.4% | US$122.0b |
CNC Centene | 14.5x | 9.1% | US$38.6b |
HUM Humana | 19.4x | 14.3% | US$37.9b |
MOH Molina Healthcare | 18.6x | 16.1% | US$19.9b |
UNH * UnitedHealth Group | 29.5x | 19.5% | Mex$445.4b |
Price-To-Earnings vs Peers: UNH * is expensive based on its Price-To-Earnings Ratio (29.5x) compared to the peer average (18x).
Price to Earnings Ratio vs Industry
How does UNH *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: UNH * is expensive based on its Price-To-Earnings Ratio (29.5x) compared to the Global Healthcare industry average (21.4x).
Price to Earnings Ratio vs Fair Ratio
What is UNH *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 29.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate UNH *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$8,300.00 | Mex$9,687.12 +16.7% | 7.7% | Mex$11,525.02 | Mex$7,854.09 | n/a | 27 |
Apr ’25 | Mex$8,164.00 | Mex$9,836.08 +20.5% | 7.5% | Mex$11,263.59 | Mex$7,842.80 | n/a | 27 |
Mar ’25 | Mex$8,320.00 | Mex$10,147.28 +22.0% | 7.3% | Mex$11,541.29 | Mex$8,036.15 | n/a | 26 |
Feb ’25 | Mex$8,663.85 | Mex$10,306.17 +19.0% | 7.1% | Mex$11,690.19 | Mex$8,139.84 | n/a | 26 |
Jan ’25 | Mex$8,953.26 | Mex$10,099.95 +12.8% | 7.4% | Mex$11,588.33 | Mex$8,240.59 | n/a | 23 |
Dec ’24 | Mex$9,386.64 | Mex$10,203.00 +8.7% | 6.2% | Mex$11,459.98 | Mex$8,681.80 | n/a | 23 |
Nov ’24 | Mex$9,620.03 | Mex$10,611.53 +10.3% | 6.6% | Mex$11,915.31 | Mex$8,340.72 | n/a | 23 |
Oct ’24 | Mex$8,786.44 | Mex$9,708.36 +10.5% | 6.6% | Mex$11,131.97 | Mex$7,912.26 | n/a | 24 |
Sep ’24 | Mex$8,146.70 | Mex$9,742.07 +19.6% | 6.7% | Mex$11,113.44 | Mex$7,899.09 | n/a | 24 |
Aug ’24 | Mex$8,493.25 | Mex$9,569.49 +12.7% | 6.8% | Mex$10,959.85 | Mex$7,789.92 | n/a | 24 |
Jul ’24 | Mex$8,247.79 | Mex$9,830.82 +19.2% | 6.8% | Mex$11,086.60 | Mex$7,880.01 | n/a | 24 |
Jun ’24 | Mex$8,697.26 | Mex$10,366.30 +19.2% | 6.6% | Mex$11,478.87 | Mex$8,158.83 | n/a | 24 |
May ’24 | Mex$8,939.38 | Mex$10,565.93 +18.2% | 6.9% | Mex$11,686.94 | Mex$8,306.71 | Mex$8,310.00 | 23 |
Apr ’24 | Mex$8,542.00 | Mex$11,190.65 +31.0% | 6.7% | Mex$12,342.33 | Mex$8,772.55 | Mex$8,164.00 | 23 |
Mar ’24 | Mex$8,600.00 | Mex$11,188.65 +30.1% | 6.4% | Mex$12,309.25 | Mex$8,749.03 | Mex$8,320.00 | 23 |
Feb ’24 | Mex$9,291.47 | Mex$11,132.59 +19.8% | 6.3% | Mex$12,235.86 | Mex$8,696.87 | Mex$8,663.85 | 23 |
Jan ’24 | Mex$10,310.00 | Mex$11,480.43 +11.4% | 7.8% | Mex$12,696.58 | Mex$8,321.14 | Mex$8,953.26 | 23 |
Dec ’23 | Mex$10,317.00 | Mex$11,305.68 +9.6% | 7.6% | Mex$12,422.82 | Mex$8,217.58 | Mex$9,386.64 | 23 |
Nov ’23 | Mex$10,802.50 | Mex$11,532.71 +6.8% | 7.6% | Mex$12,522.14 | Mex$8,400.68 | Mex$9,620.03 | 23 |
Oct ’23 | Mex$10,247.11 | Mex$11,595.12 +13.2% | 9.2% | Mex$12,818.05 | Mex$8,114.73 | Mex$8,786.44 | 24 |
Sep ’23 | Mex$10,510.00 | Mex$11,454.22 +9.0% | 9.1% | Mex$12,631.78 | Mex$8,034.77 | Mex$8,146.70 | 24 |
Aug ’23 | Mex$11,015.94 | Mex$11,719.68 +6.4% | 9.0% | Mex$12,932.74 | Mex$8,226.21 | Mex$8,493.25 | 25 |
Jul ’23 | Mex$10,408.70 | Mex$11,572.41 +11.2% | 8.9% | Mex$12,902.85 | Mex$8,207.19 | Mex$8,247.79 | 24 |
Jun ’23 | Mex$9,715.00 | Mex$11,252.13 +15.8% | 9.1% | Mex$12,500.83 | Mex$7,951.48 | Mex$8,697.26 | 23 |
May ’23 | Mex$10,387.23 | Mex$11,521.17 +10.9% | 9.1% | Mex$12,755.02 | Mex$8,113.16 | Mex$8,939.38 | 22 |
Analyst Forecast: Target price is less than 20% higher than the current share price.